China launches Hecolin, the first vaccine against hepatitis E
Like many other ailments of the emerging economies, the hepatitis E is not one of the main targets of the pharmaceutical companies. Drug development is also linked to economic part, and cure these ills is not exactly profitable. Throwing drugs to populations who can not purchase involves a financial loss, so companies must find a model that balances its interest in public health to income. Apparently in China have found a way to both get ahead.
Hepatitis E is a disease that thrives mainly in the poorest regions of Asia, Africa, Central America and South America. It occurs in countries with poor sanitary conditions, especially where access to clean water is limited. The virus infects about 20 million people each year, with 70,000 deaths. There is no treatment for this type of hepatitis, other than prevention. In most cases, the condition disappears after a few weeks, so its mortality rate is 4%, although pregnant women, rising to 20%-that is, one in five infected died.
Although the mortality rate is relatively low, disables itself for several days to the sick. Thus, many lose their ability to work, which negatively impacts on their income and endangers their support and that of their families. Although it is a public health problem, major U.S. networks do not have as one of its priorities.
It was China who has hit first with the presentation of Hecolin, the first vaccine for hepatitis E . Their arrival represents the culmination of over a decade of joint work between the Chinese authorities and the group Yangshengtang, a company focused on food and health care. Between them, formed the National Institute of Building Diagnostics and vaccines for infectious diseases, through which work in creating solutions to combat emerging diseases.’s Hecolin is the first product of this alliance to hit the market, but already in other development to combat human papillomavirus.
The case of Hecolin not only be seen as a new solution to the problem: it also represents a successful collaboration model that can bear fruit to fight disease in developing countries. China seeks not only that the vaccine remains within its borders, but speech and the World Health Organization to be within a framework that allows distributed in other nations where needed. And, of course, also a statement to the world of pharmaceutical development potential in China, an area which will soon be ready to compete with other powers in the world.Tags: China, Hecolin, Hepatitis E